Browse by Medical Category
Call for more information:
Patients of the Massachusetts General Hospital Transplant Center have access to leading-edge clinical trials and therapies including new immunosuppressive medications, tolerance induction and islet cell transplantation.
Kidney transplant patients typically take prescription drugs to keep their immune systems from rejecting their new organs. The standard drugs are effective but have many side effects including toxicity to the transplanted kidney, which tends to shorten the lifespan of the organ. Less toxic drugs have been developed to support better long-term kidney function. The Mass General Kidney Transplant Program is part of a collaboration of academic medical centers conducting clinical trials monitoring patients on these newer immunosuppressive agents. For more information, call 617-726-2631
In spite of advances over the last 50 years in anti-rejection medications, the side effects of long-term immunosuppressive therapy remain a major problem for post-transplant patients. Mass General has been a leader in developing procedures that allow transplant patients to live drug-free and without rejection. The Kidney Transplant Program at Mass General continues to improve and expand these protocols for patients with living kidney donors. For more information, call Kerry Crisalli at 617-643-4087.
The absence of insulin-producing cells in the body results in type 1 diabetes. Islet transplantation replaces the insulin-producing cells of the pancreas without the risks of major abdominal surgery and non-insulin-producing tissue that come with a whole organ pancreas transplant. Mass General is one of the few centers in the country that can isolate and transplant pancreatic islets. Islet transplantation is an option at Mass General both for patients who have had a previous kidney transplant and for those without kidney disease.
For more information on islet transplantation, call Kerry Crisalli at 617-643-4087.
Back to Top